4.2 AI explanation of Diagrams on PPTs

The L-arginine-NO pathway produces nitric oxide (NO) from the amino acid __________.

L-arginine

The enzyme responsible for converting L-arginine to NO is __________.

NO synthase

The cofactor required by NO synthase to generate NO is __________ (tetrahydrobiopterin).

BH4

After its production, nitric oxide (NO) is oxidized to __________ and then to __________.

nitrite (NO2-); nitrate (NO3-)

The alternative pathway for NO generation is the __________ pathway.

nitrate-nitrite-NO

In the nitrate-nitrite-NO pathway, dietary nitrates (NO3-) are converted to __________.

nitrite (NO2-)

Nitrite (NO2-) can be further reduced to NO by enzymes called __________.

nitrite reductases

The nitrate-nitrite-NO pathway is especially important under __________ conditions when NO synthase activity is low.

hypoxic (low oxygen)

Both the L-arginine-NO and nitrate-nitrite-NO pathways ultimately increase __________ bioavailability.

nitric oxide (NO)

Increased NO bioavailability leads to key biological effects such as vascular smooth muscle __________.

relaxation (vasodilation)

Organic nitrates such as __________ and __________ are prodrugs that release nitric oxide (NO) in vascular smooth muscle.

nitroglycerin; isosorbide dinitrate

The enzyme system responsible for converting organic nitrates to NO primarily acts in the __________ smooth muscle.

venous

Nitric oxide (NO) activates the enzyme __________, which converts GTP → cGMP.

soluble guanylyl cyclase (sGC)

The second messenger molecule produced by sGC in response to NO is __________.

cyclic GMP (cGMP)

cGMP activates the enzyme __________, which reduces intracellular calcium and leads to smooth muscle relaxation.

protein kinase G (PKG)

Vascular smooth muscle relaxation caused by nitrates results in venodilation, which decreases cardiac __________ (preload).

filling pressure / preload

At higher doses, nitrates can also cause arteriolar dilation, reducing __________ (afterload).

systemic vascular resistance / afterload

Coronary artery dilation caused by nitrates helps improve myocardial oxygen __________.

supply

The enzyme that degrades cGMP into inactive 5′-GMP is __________.

phosphodiesterase type 5 (PDE-5)

Drugs such as sildenafil, vardenafil, and tadalafil inhibit __________, thereby prolonging cGMP activity.

PDE-5

The combination of nitrates with PDE-5 inhibitors is contraindicated because it can cause severe __________ due to excessive cGMP accumulation.

hypotension

Overall, nitrates decrease myocardial oxygen demand by reducing __________ and __________, and increase oxygen supply by dilating __________ arteries.

preload; afterload; coronary

Continuous exposure to nitrates can lead to pharmacologic __________, which requires a daily nitrate-free interval.

tolerance

Common side effects of nitrate therapy include headache, flushing, and reflex __________.

tachycardia

The molecular mechanism linking NO → vasodilation can be summarized as: Organic nitrates → NO → sGC → ↑ cGMP → PKG activation → ↓ Ca²⁺ → smooth muscle __________.

relaxation

High-potency organic nitrates such as __________ and __________ are primarily bioactivated in mitochondria.

GTN (nitroglycerin); PETN (pentaerythritol tetranitrate)

The key mitochondrial enzyme responsible for nitrate bioactivation is __________.

aldehyde dehydrogenase type 2 (ALDH2)

ALDH2 catalyzes the conversion of nitrates to __________ and then to __________.

nitrite (NO2−); nitric oxide (NO·)

Nitric oxide (NO·) activates the enzyme __________, leading to an increase in __________.

soluble guanylyl cyclase (sGC); cyclic GMP (cGMP)

Activation of cGMP stimulates __________, which induces vascular smooth muscle __________.

cGK-I (protein kinase G type I); relaxation

At higher doses, high-potency nitrates can also be metabolized by the enzyme __________ in the smooth endoplasmic reticulum.

cytochrome P450

Low-potency nitrates such as __________ and __________ rely more heavily on P450 enzymes for NO generation.

ISDN (isosorbide dinitrate); ISMN (isosorbide mononitrate)

Additional enzymes such as __________ and __________ may also contribute to nitrate bioactivation under specific conditions.

cytochrome oxidase (Cyt Ox); xanthine oxidase (XO)

Regardless of the bioactivation pathway, all organic nitrates ultimately increase intracellular __________ levels to produce vasodilation.

cGMP

The final biological outcome of nitrate bioactivation is vascular smooth muscle __________ and improved coronary blood flow.

relaxation (vasodilation)

Chronic use of nitrates such as __________ can lead to reduced drug effectiveness, known as nitrate tolerance.

GTN (nitroglycerin)

One mechanism of nitrate tolerance involves oxidative inactivation of the mitochondrial enzyme __________.

ALDH2 (aldehyde dehydrogenase type 2)

When ALDH2 is oxidized (ALDH2-SH → ALDH2-SS), nitrate bioactivation and __________ production are impaired.

nitric oxide (NO·)

Reactive oxygen species such as __________ and __________ react with NO to reduce its availability.

superoxide (O2•-); peroxynitrite (ONOO-)

Depletion of the NOS cofactor __________ and formation of __________ lead to NOS uncoupling.

BH4 (tetrahydrobiopterin); BH2

NOS uncoupling results in the production of __________ instead of nitric oxide (NO·).

superoxide (O2•-)

Excess oxidative stress from NADPH oxidase and PKC activation contributes to __________ dysfunction.

endothelial

Endothelial dysfunction is characterized by decreased production of vasodilators like __________ and increased release of vasoconstrictors like __________.

PGI2 (prostacyclin); ET-1 (endothelin-1)

Neurohormonal compensation during chronic nitrate therapy (pseudo-tolerance) involves activation of the __________ system.

RAAS (renin-angiotensin-aldosterone system)

Pseudo-tolerance leads to increased levels of catecholamines, __________, and __________, promoting vasoconstriction and volume expansion.

vasopressin; intravascular volume

Overall, nitrate tolerance involves a combination of endothelial dysfunction, oxidative stress, and __________ supersensitivity.

vasoconstrictor

The result of chronic nitrate use without drug-free intervals is impaired __________ and loss of therapeutic vasodilation.

smooth muscle relaxation

Contraction of vascular smooth muscle requires the influx of __________ through L-type calcium channels.

Ca2+

Once inside the smooth muscle cell, Ca2+ binds to __________ to form a complex that activates myosin light chain kinase (MLCK).

calmodulin (CaM)

Activated MLCK phosphorylates __________ to produce smooth muscle contraction.

myosin light chain (Myosin-LC)

Calcium channel blockers reduce vascular contraction by inhibiting __________ channels.

L-type Ca2+

ACE inhibitors prevent the conversion of angiotensin I to __________, reducing vasoconstriction.

angiotensin II (AT-II)

Increased bradykinin levels from ACE inhibitor use promote the release of __________, causing vasodilation.

nitric oxide (NO)

AT1 receptor antagonists block the effects of __________ at the vascular smooth muscle, decreasing Ca2+ influx.

angiotensin II

Ranolazine inhibits the late __________ current, indirectly reducing intracellular Ca2+ and myocardial wall tension.

Na+

Nitrates are converted to __________, which increases cGMP and activates myosin light chain phosphatase.

nitric oxide (NO)

Activation of myosin light chain phosphatase leads to dephosphorylation of Myosin-LC and smooth muscle __________.

relaxation

Sildenafil inhibits the enzyme __________, which breaks down cGMP, thus enhancing NO-mediated relaxation.

phosphodiesterase type 5 (PDE-5)

K+ channel openers cause membrane __________, which closes voltage-dependent Ca2+ channels and induces relaxation.

hyperpolarization

The balance between MLCK activation and Myosin-LC phosphatase determines whether smooth muscle will __________ or __________.

contract; relax

ACE inhibitors and nitrates both increase levels of the vasodilator molecule __________.

nitric oxide (NO)

By reducing intracellular Ca2+, drugs such as CCBs and ranolazine decrease vascular __________ and myocardial oxygen demand.

tension (contractility)

In healthy endothelium, the enzyme __________ converts L-arginine to L-citrulline and nitric oxide (NO).

endothelial nitric oxide synthase (eNOS)

The essential cofactor required by eNOS for NO synthesis is __________.

tetrahydrobiopterin (BH4)

Nitric oxide (NO) produced in endothelial cells diffuses into vascular smooth muscle cells to activate the enzyme __________.

soluble guanylyl cyclase (sGC)

Activated sGC converts __________ into cyclic GMP (cGMP).

GTP

An increase in cGMP activates protein kinase G, leading to smooth muscle __________.

relaxation (vasodilation)

In endothelial dysfunction, oxidative stress oxidizes BH4 to __________, leading to eNOS uncoupling.

BH2

When eNOS becomes uncoupled, it generates __________ instead of nitric oxide (NO).

superoxide (O2•-)

Nitric oxide can react with superoxide to form the damaging molecule __________.

peroxynitrite (ONOO-)

Peroxynitrite (ONOO-) oxidizes the Fe2+ heme of sGC to Fe3+, resulting in loss of sGC __________.

activity (inactivation)

Oxidation and loss of active sGC lead to reduced __________ production and impaired vasodilation.

cGMP

The overall effect of oxidative stress and eNOS uncoupling is reduced nitric oxide __________.

bioavailability

Endothelial dysfunction ultimately leads to decreased vasodilation and increased vascular __________.

tone (constriction)